United StatesAYTU
Aytu BioPharma Set to Report Q4 2026 Earnings Monday
Aytu BioPharma is scheduled to announce its Q4 earnings results on Monday, September 21st, after market close. The consensus EPS estimate is -$0.35, which represents an 88.1% improvement year over year. The consensus revenue estimate is $12.28M, a decline of 18.7% year over year.
AYTU · Capital · Neutral Aytu is set to report Q4 earnings Monday with consensus EPS improving but revenue expected to decline 18.7% YoY.